🇺🇸 FDA
Patent

US 9683024

Recombinantly expressed plasmodium CelTOS antigen and methods of use thereof

granted A61KA61K2039/55566A61K2039/57

Quick answer

US patent 9683024 (Recombinantly expressed plasmodium CelTOS antigen and methods of use thereof) held by The United States of America as represented by the Secretary of the Army expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as represented by the Secretary of the Army
Grant date
Tue Jun 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K2039/55566, A61K2039/57, A61K39/00, A61K39/015